HC Wainwright Rates Monopar Therapeutics (MNPR) buy
HC Wainwright maintains its buy rating on MNPR with a $105 price target, a 11.04% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Monopar Therapeutics Inc. ($MNPR) "buy" with a $105 price target on June 29, 2026.
Since the rating, $MNPR is up 2.7% after 1 week, up 13.6% after 1 month and down 26.7% to date (from the $94.56 close on Jun 29, 2026).
MNPR
Monopar Therapeutics Inc.
Key Points
- On June 29, 2026, HC Wainwright reiterated its buy rating on MNPR, setting a price target of $105.
- HC Wainwright's $105 price target implies 11.04% upside from Monopar Therapeutics Inc.'s ($MNPR) current $94.56 share price.
- MNPR shares traded at $87.68 on Monday, reflecting ongoing interest from analysts and investors.
- Several institutions adjusted their MNPR holdings recently, with Deerfield Management significantly increasing its position.
Get $MNPR trade alerts by text
We text you when insiders, Congress or big funds trade $MNPR. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Monopar Therapeutics Inc. alert may contain errors. Disclosures
On June 29, 2026, HC Wainwright reiterated its buy rating for MNPR, setting a price target of $105. The analyst, Andres Y. Maldonado, reaffirmed his positive outlook on the stock. This comes as MNPR shares traded at $87.68 on Monday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in MNPR
Several institutional investors have recently adjusted their positions in MNPR. Saturn V Capital Management LP increased its holdings by 19,925 shares, a 6.1% rise, reaching a total of 345,626 shares valued at about $18.9 million. Deerfield Management Company, L.P. made a more substantial move, boosting its stake by 153,187 shares, an 89.8% increase, ending with 323,745 shares worth approximately $17.7 million. BlackRock, Inc. also added 61,710 shares, representing a 24.2% increase, bringing its total to 316,567 shares valued at $17.3 million. Conversely, Adage Capital Partners GP, L.L.C. reduced its position by 330,272 shares, a 51.6% decrease, leaving it with 309,195 shares valued at $16.9 million.
Monopar Therapeutics Inc. Stock Down 2.0%
MNPR shares traded near $87.68 on Monday. The stock's performance continues to attract attention from analysts and investors alike.
$MNPR price target
Monopar Therapeutics Inc. daily closes and this analyst's $105 target. Not advice.
Insider Buying and Selling at Monopar Therapeutics Inc.
Recent insider activity at MNPR has shown several executives increasing their stakes. On March 2, 2026, Susan Rodriguez, the CCSO, acquired 48,728 shares. Earlier, on January 1, 2026, Patrice Rioux purchased 2,000 shares. Chandler Robinson, the CEO, bought 62,815 shares on January 28, 2025. These transactions suggest confidence in the company's future prospects.
Analysts Set New Price Targets
On June 29, 2026, HC Wainwright & Co. reiterated its buy rating on MNPR, setting a price target of $105. Previously, on March 30, 2026, Chardan Capital maintained its buy rating with a $100 target. BTIG also reaffirmed its buy rating with a $104 target on January 14, 2026. The stock enjoys a consensus recommendation of 'buy', with an average price target of $105 based on multiple analyst opinions.
Bottom Line
The reiteration of a buy rating by HC Wainwright with a $105 target reflects ongoing confidence in MNPR's potential. Institutional and insider activities indicate varied strategies, with some increasing their stakes significantly. As always, investors should note that these ratings and holdings are based on past data and may not represent current positions.
Related Filing Alerts
Source: HC Wainwright's rating change on $MNPR (Jun 29, 2026). Written by software, not financial advice. How we make alerts